Literature DB >> 11508669

Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis.

S Kato1, K Suzuki, H Ukawa, Y Komoike, K Takeuchi.   

Abstract

The gastric toxic effects of aspirin (ASA) and NCX-4016, a nitric oxide (NO)-releasing ASA, were compared in normal, cirrhotic, and arthritic rats. Oral administration of ASA (100 mg/kg) produced hemorrhagic lesions on the gastric mucosa in normal rats. The gastric ulcerogenic response to ASA was significantly worsened in both cirrhotic rats induced by N-nitrosodiethylamine and in arthritic rats induced by Freund's complete adjuvant. By contrast, NCX-4016 at 190 mg/kg (a dose equimolar to 100 mg/kg of ASA) did not induce damage in normal rat stomachs but caused slight lesions in the gastric mucosa of both cirrhotic and arthritic rats. Plasma salicylate levels following administration of ASA or NCX-4016 were not different between normal, cirrhotic, and arthritic rats, although the latter drug gave significantly lower values in any group of rats as compared to the former. Acid secretion was significantly increased in both cirrhotic and arthritic rats. ASA with 150 mM HCl caused severe gastric lesions in normal rats, the degree of damage being significantly greater than that induced by ASA alone. Coadministration of NOR-3, a NO donor, significantly prevented the development of gastric lesions induced by ASA, irrespective of whether or not ASA was given together with HCl. Gastric mucosal application of ASA (100 mg/kg) for 30 min caused a marked reduction of transmucosal potential difference (PD) with a minimal effect on gastric mucosal blood flow in both normal and cirrhotic rats, while that of NCX-4016 did not cause a PD reduction and produced a marked increase in the mucosal blood flow in both groups of rats. These results suggest that gastric mucosal susceptibility to ASA-induced damage is increased in both cirrhotic and arthritic rats (the process being partly accounted for by acid hypersecretion in these animals), NCX-4016 has even less gastric toxicity in both cirrhotic and arthritic rats, and the gastric-sparing effect of NCX-4016 is due, at least partly, to an increase of gastric mucosal blood flow, mediated by NO released from this drug.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508669     DOI: 10.1023/a:1010601520497

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat.

Authors:  B J Whittle; J Lopez-Belmonte; S Moncada
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

2.  Gastric mucosal hemorrhage in dogs. Effects of acid, aspirin, and alcohol.

Authors:  H W Davenport
Journal:  Gastroenterology       Date:  1969-03       Impact factor: 22.682

3.  Changes in gastric mucosal ulcerogenic responses in rats with adjuvant arthritis: role of nitric oxide.

Authors:  S Kato; A Tanaka; T Kunikata; M Nishijima; K Takeuchi
Journal:  Aliment Pharmacol Ther       Date:  1999-06       Impact factor: 8.171

4.  Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.

Authors:  J L Wallace; W McKnight; P Del Soldato; A R Baydoun; G Cirino
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process.

Authors:  J L Wallace; C M Keenan; D N Granger
Journal:  Am J Physiol       Date:  1990-09

6.  Role of nitric oxide in regulation of gastric acid secretion in rats: effects of NO donors and NO synthase inhibitor.

Authors:  S Kato; M Kitamura; R P Korolkiewicz; K Takeuchi
Journal:  Br J Pharmacol       Date:  1998-03       Impact factor: 8.739

7.  Nitric oxide prevents leukocyte adherence: role of superoxide.

Authors:  J Gaboury; R C Woodman; D N Granger; P Reinhardt; P Kubes
Journal:  Am J Physiol       Date:  1993-09

8.  Mucosal lesions of the stomach in liver cirrhosis with a special reference to phospholipid metabolism.

Authors:  Y Hosokawa
Journal:  Gastroenterol Jpn       Date:  1991-06

9.  Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409.

Authors:  Y Kita; Y Hirasawa; K Maeda; M Nishio; K Yoshida
Journal:  Eur J Pharmacol       Date:  1994-05-12       Impact factor: 4.432

10.  Mechanisms involved in Helicobacter pylori-induced inflammation.

Authors:  N Yoshida; D N Granger; D J Evans; D G Evans; D Y Graham; D C Anderson; R E Wolf; P R Kvietys
Journal:  Gastroenterology       Date:  1993-11       Impact factor: 22.682

View more
  4 in total

Review 1.  Risk factors for gastrointestinal complications in aspirin users: review of clinical and experimental data.

Authors:  Felix W Leung
Journal:  Dig Dis Sci       Date:  2008-02-28       Impact factor: 3.199

2.  Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs.

Authors:  Mitali Chattopadhyay; Carlos A Velazquez; April Pruski; Kamran V Nia; Khaled R Abdellatif; Larry K Keefer; Khosrow Kashfi
Journal:  J Pharmacol Exp Ther       Date:  2010-08-02       Impact factor: 4.030

Review 3.  Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs.

Authors:  J E Keeble; P K Moore
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

4.  NCX 4016, a nitric oxide-releasing aspirin, modulates adrenergic vasoconstriction in the perfused rat tail artery.

Authors:  Giuseppe Rossoni; Barbara Manfredi; Piero Del Soldato; Ferruccio Berti
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.